TOKYO -- AstraZeneca has begun clinical trials for a coronavirus vaccine candidate in Japan, its local unit announced Friday.
The U.K.-headquartered company is the third to start such trials in the country, after AnGes, a drugmaker that was founded at Osaka University, and U.S.-based Johnson & Johnson. If successful, it could become one of the top suppliers for coronavirus vaccines in Japan.